Drugs / POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS

Trials 2 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT01329042 May 2005 → Oct 2007 nephrolithiasis, calcium oxalate Ouiheng International Healthcare Co., Ltd Completed No outcome recorded
Phase not applicable1 trial
NCT04352153 Apr → Sep 2020 urolithiasis Ai Peng Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03924596 Comparator Sep 2019 → Sep 2020 urolithiasis Sultan Qaboos University Unknown No outcome recorded
Phase not applicable1 trial
NCT06814834 Comparator Dec 2023 → Dec 2024 nephrolithiasis Cairo University Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764
Known as Cg 120 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764
Known as Potassium-sodium citrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT01329042
Known as potassium-sodium-hydrogen-citrate “Patients received guidance for oral potassium-sodium-hydrogen-citrate (6:6:3:5) at a dosage of twenty milliequivalents three times every day” NCT06814834
1

NCT03924596

Known as Solimok ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764
Known as Uralyt-U ClinicalTrials.gov intervention name — accepted as the source's own label NCT04352153
Modality Small molecule CHEMBL6068764
Route Oral “given oral potassium-sodium citrate” NCT01329042